“Trogarzo® continues to be a crucial treatment option for patients with multidrug-resistant (MDR) HIV. At TaiMed Biologics, our mission is to expand its global accessibility through strategic partnerships, ensuring that more patients in need can benefit from this life-saving therapy. Over the past year, we have successfully extended Trogarzo®’s reach beyond the U.S. to regions including the Middle East, North Africa, Hong Kong, Macau, and Taiwan through collaborations with new partners. In these areas, limited treatment options have long posed challenges, and the availability of Trogarzo® marks a significant advancement in addressing these unmet medical needs. Moving forward, we remain committed to expanding into additional markets, bringing the benefits of Trogarzo® to even more patients worldwide,” said Jimmy Chang, Ph.D., CEO of TaiMed Biologics.
About Trogarzo® (Ibalizumab-uiyk):
Trogarzo® (ibalizumab-uiyk) is a groundbreaking innovation in HIV therapy, representing the world’s first approved monoclonal antibody for HIV treatment with a long-acting effect. By targeting CD4 receptors, it acts as a post-attachment HIV-1 inhibitor, preventing viral entry into CD4+ cells. Currently, Trogarzo® is the only monoclonal antibody approved for HIV treatment. When used in combination with other antiretroviral agents, it is indicated for heavily treatment-experienced adults with multidrug-resistant (MDR) HIV-1 infection who have failed their current antiretroviral regimen.
Trogarzo® is approved by the U.S. FDA for intravenous administration via infusion or IV push (undiluted form) every two weeks. It is gradually becoming available in other countries and regions.
About TaiMed Biologics
TaiMed Biologics (4147.TWO), founded in 2007 in Taiwan, is a leading commercial-stage biotechnology company dedicated to developing innovative therapies for HIV treatment. TaiMed successfully developed ibalizumab (Trogarzo®), the first-in-class monoclonal antibody for HIV, which received U.S. FDA approval in 2018. The company is also focused on developing long-acting biologics and antibody-drug conjugates (ADC) for HIV therapy.
In addition to its R&D efforts, TaiMed offers comprehensive contract development and manufacturing (CDMO) services to pharmaceutical clients. The company has been publicly traded on the OTC Market since November 2015 and is currently part of the MSCI Small Cap Index.
About Slim Pharmaceuticals
Slim Pharmaceuticals (Pvt) Ltd, established in 2011 and headquartered in Sri Lanka, is a leading distributor of high-quality pharmaceuticals. The company partners with globally recognized pharmaceutical manufacturers to establish a robust nationwide distribution network, delivering innovative and reliable medical products to both the public and private healthcare sectors. With a professional team and efficient logistics support, Slim Pharmaceuticals is well-positioned to respond swiftly to market demands, continuously meeting the growing needs of Sri Lanka’s healthcare industry and building a trusted brand within the sector.
Contact CDMO Service